MMP-9 inhibition by ACE inhibitor reduces oxidized LDL-mediated foam-cell formation

Journal of Atherosclerosis and Thrombosis

Volumn 17, Issue 1, 2010, Pages 97-105

  Kojima, Chiari ^a,b   Ino, Jun ^a,b   Ishii, Hideto ^a   Nitta, Kosaku ^b   Yoshida, Masayuki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

ACE inhibitor; Foam cell formation; MMP 9; Oxidized LDL; Scavenger receptors

Indexed keywords

CD36 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE A; GELATINASE B; IMIDAPRILAT; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; OXIDIZED LOW DENSITY LIPOPROTEIN; SCAVENGER RECEPTOR A; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; ATHEROGENESIS; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; FOAM CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; IN VITRO STUDY; LIPID ANALYSIS; LIPID STORAGE; MACROPHAGE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SUPERNATANT;

EID: 76249129796     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.1685     Document Type: Article

References (33)

1. Prasad A, Quyyumi AA: Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation, 2004; 110: 1507-1512
2. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 2000; 342: 145-153
3. Lonn E, Yusuf S, Dzavik V, Doris C, Yi Q. L, Smith S, Moore-Cox A, Bosch J, Riley W, Teo K. SECURE Investigators: Effects of ramipril and vitamin E on atherosclerosis - The study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation, 2001; 103: 919-925
4. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med, 2005; 352: 1685-1695
5. Miller YI, Chang MK, Binder CJ, Shaw PX, Witztum JL: Oxidized low density lipoprotein and innate immune receptors. Curr Opin Lipidol, 2003; 14: 437-445
6. Hayek T, Kaplan M, Raz A, Keidar S, Coleman R, Aviram M: Ramipril administration to atherosclerotic mice reduces oxidized low-density lipoprotein uptake by their macrophages and blocks the progression of atherosclerosis. Atherosclerosis, 2002; 161: 65-74
7. Scheidegger KJ, Butler S, Witztum JL: Angiotensin II increases macrophage-mediated modification of low density lipoprotein via a lipoxygenase-dependent pathway. J Biol Chem, 1997; 272: 21609-21615
8. Hayek T, Attias J, Coleman R, Brodsky S, Smith J, Breslow JL, Keidar S: The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice. Cardiovas Res, 1999; 44: 579-587
9. Chen R, Iwai M, Wu L, Suzuki J, Min LJ, Shiuchi T, Sugaya T, Liu HW, Cui TX, Horiuchi M: Important role of nitric oxide in the effect of angiotensin-converting enzyme inhibitor imidapril on vascular injury. Hypertension, 2003; 42: 542-547
10. da Cunha V, Tham DM, Martin-McNulty B, Deng G, Ho JJ, Wilson DW, Rutledge JC, Vergona R, Sullivan ME, Wang YX: Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. Atherosclerosis, 2005; 178: 9-17
11. Kohlstedt K, Busse R, Fleming I: Signaling via the angiotensin-converting enzyme enhances the expression of cyclooxygenase-2 in endothelial cells. Hypertension, 2005; 45: 126-132
12. Kojima C, Kawakami A, Takei T, Nitta K, Yoshida M: Angiotensin-converting enzyme inhibitor attenuates monocyte adhesion to vascular endothelium through modulation of intracellular zinc. J Pharmacol Exp Ther, 2007; 323: 855-860
13. Yamamoto D, Takai S, Miyazaki M: Prediction of interaction mode between a typical ACE inhibitor and MMP-9 active site. Biochem Biophys Res Commun, 2007; 354:981-984
14. Yamamoto D, Takai S, Jin D, Inagaki S, Tanaka K, Miyazaki M: Molecular mechanism of imidapril for cardiovascular protection via inhibition of MMP-9. J Mol Cell Cardial, 2007; 43: 670-676
15. Reinhardt D, Sigusch HH, Hensse J, Tyagi SC, Korfer R, Figulla HR, Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart, 2002; 88: 525-530
16. Sakata Y, Yamamoto K, Mano T, Nishikawa N, Yoshida J, Hori M, Miwa T, Masuyama T: Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of Angiotensin-converting enzyme inhibitor. Circulation, 2004; 109: 2143-2149
17. Galis ZS, Sukhova GK, Lark MW, Libby P: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest, 1994; 94: 2493-2503
18. Suzuki H, Kobayashi H, Sato F, Yonemitsu Y, Nakashima Y, Sueishi K: Plaque-stabilizing effect of pitavastatin in Watanabe heritable hyperlipidemic (WHHL) rabbits. J Atheroscler Thromb, 2003; 10: 109-116
19. Wilson WR, Anderton M, Schwalbe EC, Jones JL, Furness PN, Bell PR, Thompson MM: Matrix metalloproteinase-8 and -9 are increased at the site of abdominal aortic aneurysm rupture. Circulation, 2006; 113: 438-445
20. Kang JH, Kim JK, Park WH, Park KK, Lee TS, Magae J, Nakajima H, Kim CH, Chang YC: Ascochlorin suppresses oxLDL-induced MMP-9 expression by inhibiting the MEK/ERK signaling pathway in human THP-1 macrophages. J Cell Biochem, 2007; 102: 506-514
21. Xu XP, Meisel SR, Ong JM, Kaul S, Cercek B, Rajavashisth TB, Sharifi B, Shah PK: Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation, 1999; 99: 993-998
22. Luttun A, Lutgens E, Manderveld A, Maris K, Collen D, Carmeliet P, Moons L: Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation, 2004; 109: 1408-1414
23. Li D, Singh RM, Liu L, Chen H, Singh BM, Kazzaz N, Mehta JL: Oxidized-LDL through LOX-1 increases the expression of angiotensin converting enzyme in human coronary artery endothelial cells. Cardiovas Res, 2003; 57:238-243
24. Li D, Saldeen T, Romeo F, Mehta JL: Oxidized LDL upregulates angiotensin II type 1 receptor expression in cultured human coronary artery endothelial cells: the potential role of transcription factor NF-kappaB. Circulation, 2000; 102: 1970-1976
25. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, Ueno T, Sugi K, Imaizumi T: Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol, 1998; 32: 368-372
26. Li L, Renier G: The oral anti-diabetic agent, gliclazide, inhibits oxidized LDL-mediated LOX-1 expression, metalloproteinase-9 secretion and apoptosis in human aortic endothelial cells. Atherosclerosis, 2009; 204: 40-46
27. Deigner HP, Claus R: Stimulation of mitogen activated protein kinase by LDL and oxLDL in human U-937 macrophage-like cells. FEBS Lett, 1996; 385: 149-153
28. Kusuhara M, Chait A, Cader A, Berk BC: Oxidized LDL stimulates mitogen-activated protein kinases in smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol, 1997; 17: 141-148
29. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, Lusis AJ: Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation, 1995; 91: 2488-2496
30. Kataoka H, Kume N, Miyamoto S, Minami M, Moriwaki H, Murase T, Sawamura T, Masaki T, Hashimoto N, Kita T: Expression of lectinlike oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions. Circulation, 1999; 99: 3110-3117
31. Chen H, Li D, Sawamura T, Inoue K, Mehta JL: Upregulation of LOX-1 expression in aorta of hypercholesterolemic rabbits: modulation by losartan. Biochem Biophys Res Commun, 2000; 276: 1100-1104
32. Li L, Sawamura T, Renier G: Glucose enhances human macrophage LOX-1 expression: role for LOX-1 in glucose-induced macrophage foam cell formation. Circ Res, 2004; 94: 892-901
33. Yamamoto D, Takai S, Miyazaki M: Inhibitory profiles of captopril on matrix metalloproteinase-9 activity. Eur J Pharmacol, 2008; 588: 277-279